Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. - Wikidata - wikimedia - TriplyDB

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge.

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge.

http://www.wikidata.org/entity/Q34437167

about

The 2014–2015 Ebola outbreak in West Africa: Hands On A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA Ebola virus disease and critical illness.Clinical development of Ebola vaccines Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based Constructs The evolution of poxvirus vaccines Middle East respiratory syndrome: obstacles and prospects for vaccine development Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice Additives for vaccine storage to improve thermal stability of adenoviruses from hours to months A Rapid Screening Assay Identifies Monotherapy with Interferon-ß and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?A Perspective on the Development of Plant-Made Vaccines in the Fight against Ebola Virus Transcriptomic analysis reveals a previously unknown role for CD8+ T-cells in rVSV-EBOV mediated protection.Ebola exposure, illness experience, and Ebola antibody prevalence in international responders to the West African Ebola epidemic 2014-2016: A cross-sectional study.Ebola Vaccine: How Far are we?New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model.Camouflage and misdirection: the full-on assault of ebola virus disease Ebola outbreak in Western Africa 2014: what is going on with Ebola virus?Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus.Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, doub Ebola vaccine R&D: Filling the knowledge gaps.Closer than ever to an Ebola virus vaccine.Next-generation sequencing reveals a controlled immune response to Zaire Ebola virus challenge in cynomolgus macaques immunized with vesicular stomatitis virus expressing Zaire Ebola virus glycoprotein (VSVΔG/EBOVgp).Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling.Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination.Ebolavirus in West Africa, and the use of experimental therapies or vaccines.Human Ebola virus infection results in substantial immune activation.Ebola Conquers West Africa - More to Come?A Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and Primates.Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola Vaccine A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection A Kunjin Replicon Virus-like Particle Vaccine Provides Protection Against Ebola Virus Infection in Nonhuman Primates.Next Steps for Ebola Vaccination: Deployment in Non-Epidemic, High-Risk Settings.One Health: Addressing Global Challenges at the Nexus of Human, Animal, and Environmental Health.Towards detection and diagnosis of Ebola virus disease at point-of-care.Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.Fighting Ebola: A Window for Vaccine Re-evaluation?Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform.Analysis of T cell responses to chimpanzee adenovirus vectors encoding HIV gag-pol-nef antigen

P2860

Q24049114-564BCAD1-FE5A-4C1F-8F69-55B2DA316FD9 Q24289279-3990769F-5940-46B9-8C87-99EB448FA1F0 Q26250274-D1725C53-7743-47F5-9631-A976701E71C5 Q26775792-154AE9D9-B4EB-4B3F-B36C-671A1394F2BC Q26782083-EE364809-9C3E-4F0C-934D-E53B9894D763 Q26995905-2F8541D4-8532-4687-8301-090401AC0792 Q27013314-4B646C6F-7791-47CD-879A-F29C6CF80A62 Q27303766-5582AE53-05E1-4A66-964A-8973085C5D27 Q27980656-8EDA8B24-1D9C-4002-A58D-53F59EB449F9 Q28552295-413CF053-ED24-419B-9C60-9EFD3DE21CDB Q29994671-FD8AFCC6-D323-4102-87B7-F3A878DD56B0 Q30235073-AC0D9C4C-BB54-41EC-ACAD-30927A5B513F Q33681247-5F87642B-7F58-4B43-8AB9-D1F1C4F584CA Q33693686-31E6C35D-2F07-4596-8D67-7579F7C2709F Q33831877-BAC6B36C-30CD-4C47-8861-9B321AE1FFDE Q33868760-F2A2B03B-B147-4E3F-AF05-D66B2FA29482 Q34449079-E6E50CDB-EEE1-45A1-9B8D-9CD39B011764 Q34461142-5B5FD4F4-A5C0-4DCF-B1DD-7595D49050A9 Q34463780-442DCA17-D7A2-4EA5-9849-12A20B621B85 Q34468847-B26D40FF-FB64-404F-BB00-B2828765C8E6 Q34500955-0F6FB4BE-4460-4AD3-9026-3BC317EC4F3D Q34504883-236B9A6E-509C-4607-BE9E-E711D43AE05B Q34553720-A4EDEFB1-B0A7-4585-893F-D5F0C52C9A14 Q35122795-F737EDBE-B841-4694-B38D-97D40DEFFCA5 Q35183935-0E628286-78C2-44B7-ABBD-51D5E19F418B Q35189847-2D3F2F1F-0AA1-47DC-90AF-70ED7B60D6E9 Q35305323-8C68F027-67AA-4A97-B520-C70EA3A2FD5F Q35485277-6FC57244-1502-4053-A3AD-3AA4F4972B4E Q35688188-B2D66DEA-DEC4-42E1-B5CF-1FDC25490835 Q35849628-9284B3B8-F50C-48C1-860D-DC90BD974D3E Q35917496-5026A14F-AE02-40A8-AD36-F9E50A16DE6A Q35917501-8540F391-CA7D-428C-99B1-F16AF641EF0A Q36043170-1EA8420F-1437-45AB-90F8-A2617AE42407 Q36107075-C287A375-9942-4497-9E2A-6ACB049E3050 Q36133988-5E6B338E-0884-4BD5-89EA-543F871D7C10 Q36148222-E07B13FE-E8D2-4F36-A4EF-3D7F8D7A8C1F Q36239796-AAD554C2-AFEC-44EE-B2C3-C8EC602D4218 Q36247762-E3541D78-D499-496C-B4F8-007E244C00E7 Q36330007-11630693-4C39-406C-B862-E97A7977EEAB Q36369321-3DA7EE72-7A0F-43B3-B846-2E03373234EB

P2860

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge.

http://www.wikidata.org/entity/Q34437167

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Chimpanzee adenovirus vaccine ...... against ebolavirus challenge.

@ast

Chimpanzee adenovirus vaccine ...... against ebolavirus challenge.

@en

Chimpanzee adenovirus vaccine ...... against ebolavirus challenge.

@nl

type

label

Chimpanzee adenovirus vaccine ...... against ebolavirus challenge.

@ast

Chimpanzee adenovirus vaccine ...... against ebolavirus challenge.

@en

Chimpanzee adenovirus vaccine ...... against ebolavirus challenge.

@nl

prefLabel

Chimpanzee adenovirus vaccine ...... against ebolavirus challenge.

@ast

Chimpanzee adenovirus vaccine ...... against ebolavirus challenge.

@en

Chimpanzee adenovirus vaccine ...... against ebolavirus challenge.

@nl

P1433

Q34437167-2A7D3771-0EF7-4649-9AE0-7E4C5A7A613B

P1476

Q34437167-91943DF0-0E49-44F5-AAE7-BE15F9D1770D

P2093

Q34437167-23CB5A2A-C711-44DF-85F6-FE7714C486EA

Q34437167-32E07165-5816-4B7C-9C2F-5AEBC36F4B3D

Q34437167-361140AC-64B7-42C8-8D86-D209E3166307

Q34437167-5239A15F-47F3-4A9B-9005-D2D562DFEC80

Q34437167-7C9BFA50-F4FD-4CC4-87B4-7A9E172BBFF1

Q34437167-888BD193-7299-4623-8231-145AE65D8034

Q34437167-88D4542C-5A09-4E98-963D-3691C800C476

Q34437167-8CE6E544-C15F-43BE-A853-7A436E10539C

Q34437167-9E930420-01C5-4818-AE59-1EE65A0BF345

Q34437167-BD3275D9-04A9-4124-A008-3CDA039FD84B

P2860

Q34437167-19A74C94-178A-4876-91E2-AD1F70787BA9

Q34437167-1B564E60-122D-4117-9BE8-BC9B16249597

Q34437167-1DBD8807-F49D-4DC7-9C43-B216635EE00B

Q34437167-207F7E6E-FAC5-46E9-A625-B703496BFECE

Q34437167-30E3BA9E-4FCC-441F-975C-B1ED38AAD670

Q34437167-33DCFFC1-7CB7-4EF2-9A2B-3D37FFFD8706

Q34437167-38744118-FF10-4794-9AE8-708843216236

Q34437167-6DAACC3E-3A10-4AEE-B8A1-DFF0FB714670

Q34437167-6ED5DEFF-1BAE-4CC1-A4C3-73A5D7F0F94F

Q34437167-6EDD4EE0-DD90-4059-87D6-775EA9622FA5

P2888

Q34437167-277442DE-AA61-49A4-8953-0FFA23654A1D

P304

Q34437167-7A0D69DA-C781-4C01-BB69-F665B34E6137

P31

Q34437167-93DD8679-E97F-4213-8413-5C8D756EE02A

P356

Q34437167-F8868B2C-89D3-4ABF-8C3D-68B168A77E57

P407

Q34437167-F9BD1E82-B7A2-4476-8BA1-CFB4234B0789

P433

Q34437167-6E236925-B3D7-40FD-93CE-C600BD1C413B

P478

Q34437167-BB11F9C9-C305-4E13-B597-C84E046B6C6F

P50

Q34437167-26445BDE-3E27-4746-B31C-1213AA92116E

Q34437167-4111B3AB-B030-4013-8DF6-F16C285A20A9

Q34437167-4CCC9CD9-07E0-42BE-9B9E-24E347CF5ADE

Q34437167-A0EEA8D5-0FD5-4567-B2AA-3AF858B38080

Q34437167-AD346D57-C49B-4B47-A636-47E5CB86E437

Q34437167-C576A219-68B7-4633-B5F5-2152DE093A7B

P577

Q34437167-AD7F2C65-7519-4ED6-AC36-F6EF5B2FAC5C

P5875

Q34437167-9EFBE20C-1140-4060-8D76-8FFDF12361E1

P6179

Q34437167-912D228A-E8BE-4E24-995B-738E61732346

P698

Q34437167-C4BFA81A-FC71-4C23-9E9F-F9CCC673F083

P921

Q34437167-3639EC8F-85C1-4E05-A952-D441CD38B46B

P356

P1433

Nature Medicine

P1476

Chimpanzee adenovirus vaccine ...... against ebolavirus challenge.

@en

P2093

Adele Abbate

http://www.w3.org/2001/XMLSchema#string

Alfredo Nicosia

http://www.w3.org/2001/XMLSchema#string

Antonella Folgori

http://www.w3.org/2001/XMLSchema#string

Cheng Cheng

http://www.w3.org/2001/XMLSchema#string

Clement Asiedu

http://www.w3.org/2001/XMLSchema#string

Daphne A Stanley

http://www.w3.org/2001/XMLSchema#string

Fabiana Grazioli

http://www.w3.org/2001/XMLSchema#string

John C Trefry

http://www.w3.org/2001/XMLSchema#string

Kathryn E Foulds

http://www.w3.org/2001/XMLSchema#string

Lingshu Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates

Transcriptional profiling of the circulating immune response to lassa virus in an aerosol model of exposure

Development of a preventive vaccine for Ebola virus infection in primates

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials

Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs

Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major

T-cell quality in memory and protection: implications for vaccine design

Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses

Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species

Chimpanzee adenovirus vaccine protects against Zaire Ebola virus.

P2888

P304

1126-1129

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.3702

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Joshua C Johnson

Annie W Lau-Kilby

P577

2014-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265392110

http://www.w3.org/2001/XMLSchema#string

P6179

1048732037

http://www.w3.org/2001/XMLSchema#string

P698

25194571

http://www.w3.org/2001/XMLSchema#string

P921